1800 Owens Street
Suite 900
San Francisco, CA 94158
United States
415 906 4324
https://www.vir.bio
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 587
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. | CEO & Director | 4.47M | N/A | 1969 |
Mr. Sung H. Lee | Executive VP & CFO | 968.45k | N/A | 1970 |
Dr. Ann M. Hanly Ph.D. | Executive VP & Chief Technology Officer | 896.07k | N/A | 1970 |
Dr. Jeff Calcagno M.D. | Executive VP & Chief Business Officer | 860.49k | N/A | 1961 |
Dr. Klaus Frueh Ph.D. | Co-Founder & Scientific Advisor | 177.66k | N/A | 1960 |
Dr. Lawrence Corey M.D. | Co-Founder & Scientific Advisor | N/A | N/A | 1948 |
Dr. Louis J. Picker M.D. | Co-Founder & Scientific Advisor | N/A | N/A | N/A |
Dr. Jennifer Eileen Towne Ph.D. | Executive VP & Chief Scientific Officer | N/A | N/A | N/A |
Ms. Heather Rowe Armstrong | Vice President of Investor Relations | N/A | N/A | N/A |
Ms. Vanina De Verneuil J.D. | Executive VP, General Counsel & Corporate Secretary | N/A | N/A | N/A |
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies. The company was incorporated in 2016 and is headquartered in San Francisco, California.
Vir Biotechnology, Inc.’s ISS Governance QualityScore as of April 29, 2024 is 6. The pillar scores are Audit: 6; Board: 4; Shareholder Rights: 8; Compensation: 8.